Increasing prevalence of autoimmune diseases among people drives the growth of the global antinuclear antibody test market.
PORTLAND, Ore., Sept. 1, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software & Services), by Technique (ELISA, Immunofluorescence Assay, Multiplex Assay), by Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Scleroderma, Others), by End-use (Hospitals, Clinical Laboratories, Physician Office Laboratories, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global antinuclear antibody test industry was estimated at $1.3 billion in 2021, and is anticipated to hit $5.0 billion by 2031, registering a CAGR of 15.0% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape.
Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/4259
Determinants of growth-
Increasing prevalence of autoimmune diseases among people drives the growth of the global antinuclear antibody test market. Moreover, the fact that antinuclear antibody tests are becoming more and more popular as a way to diagnose autoimmune diseases such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, and others has supplemented the growth even more. Moreover, growing government healthcare insurance and rising awareness about autoimmune disorders are expected to create lucrative opportunities in the industry.
Covid-19 scenario-
- The outbreak of the pandemic impacted the global antinuclear antibody test market negatively since the majority of people were getting these tests to monitor their health and evaluate their risk for autoimmune illnesses during the crisis.
- Increasing frequency of chronic diseases and rising elderly population are the major causes behind the market expansion.
Scope of the Report: -
Report Attribute | Details |
Revenue forecast in 2030 | $ 5 billion |
Growth rate | CAGR of 15% from 2022 to 2031 |
Forecast period | 2022 - 2031 |
Regional scope | North America, Europe, Asia Pacific, Latin America, MEA |
Key companies profiled | Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc. |
Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/4259?reqfor=covid
The Reagents & Assay Kitssegment to dominate by 2031-
By product, the reagents & assay kits segment contributed to around three-fifths of the global antinuclear antibody test market share in 2021, and is expected to lead the trail by 2031. The same segment would also garner the fastest CAGR of 15.53% during the forecast period. Rise in the use of these kits for various research and development purposes for a better understanding of various types of diseases drives the segment growth.
The ELISAsegment to maintain the lion's share-
Based on technique, the ELISA segment generated around two-fifths of the global antinuclear antibody test market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also portray the fastest CAGR of 15.67% from 2022-2031. This is because the ELISA test is quick and produces data more quickly than other testing methods.
The rheumatoid Arthritissegment to retain its dominance-
Based on application, the rheumatoid arthritis segment held more than two-thirds of the global antinuclear antibody test market revenue in 2021. The same segment would also manifest the fastest CAGR of 15.46% from 2022 to 2031. This is attributed to the growing elderly population and increase in cases of rheumatoid arthritis across the world.
Purchase Inquire:
https://www.alliedmarketresearch.com/purchase-enquiry/4259
The hospitals segment to maintain the lion's share-
By end-use, the hospitals segment contributed to around two-fifths of the global antinuclear antibody test market share in 2021, and is expected to retain its dominance by 2031. Increase in patient satisfaction, outpatient services, and enhanced home care facilities offered by hospitals fuel the growth of the segment. The physician office laboratories segment, on the other hand, is expected to exhibit the fastest CAGR of 15.97% from 2022 to 2031.
North America garnered the major share in 2021-
Based on region, North America held the major share in 2021, generating nearly two-fifths of the global antinuclear antibody test market. Increasing prevalence of autoimmune illnesses propels the market growth. The Asia-Pacific region, simultaneously, would cite the fastest CAGR of 17.1% throughout the forecast period. With the growing population on board, the likelihood of developing autoimmune diseases has increased significantly. The other provinces studied through the report include Europe and LAMEA.
Key players in the industry-
- Bio-Rad Laboratories, Inc.
- Erba Diagnostics
- Thermo Fisher Scientific
- Antibodies Incorporated
- Trinity Biotech Plc.
- Immuno Concepts NA Ltd.
- ZEUS Scientific, Inc.
- Inova Diagnostics, Inc.
- EUROIMMUN Medizinische Labordiagnostika AG
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter
"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."
Trending Reports in Healthcare Industry (Book Now with 10% Discount + Covid-19 scenario):
Cosmetic Surgery Market By Gender (Female, Male), By Age Group (13 to 29, 30 to 54, 55 and above), By Procedure (Breast augmentation, Eyelid surgery, Liposuction, Rhinoplasty, Others), By End User (Ambulatory surgical facility, Hospital and clinic, Office and cosmetic surgical center): Global Opportunity Analysis and Industry Forecast, 2021-2031
Neurothrombectomy Devices Market by Product Type (Clot Retrieval Devices, Aspiration Devices, Snares), by End User (Hospitals, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Diabetic Nephropathy Market by Drugs Class (Angiotensin-converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blocker, Diuretics, Renin Inhibitor, Others), by Type (Type-1 Diabetes, Type-2 Diabetes), by Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
Neuromonitoring Devices Market by Product (Intracranial Pressure Monitoring, Cerebral Oximeter, Near Infrared Spectroscopy, Speckle Imaging, Doppler Ultrasound, EEG, Fetal/Neonatal Neuro-Monitoring Devices, Micro Ultrasound, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
Computer-Aided Drug Discovery Market by Type (Structure Based Drug Design, Ligand-Based Drug Design, Sequence-Based Approaches), by Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, Others), by End User (Pharmaceutical Companies, Biotechnology Companies, Research Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2030.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
